Prazosin
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.90 | $87.00 (0%) | 🛒 Add to cart |
| 60 | $2.43 | $174.00 $146.00 (16%) | 🛒 Add to cart |
| 90 | $2.28 | $261.00 $205.00 (21%) | 🛒 Add to cart |
| 120 | $2.20 | $348.00 $264.00 (24%) | 🛒 Add to cart |
| 180 | $2.12 | $522.00 $381.00 (27%) | 🛒 Add to cart |
| 270 | $2.07 | $783.00 $558.00 (29%) | 🛒 Add to cart |
| 360 | $2.05
Best per pill | $1044.00 $737.00 (29%) | 🛒 Add to cart |
Synonyms | |||
More info:
Nimotop: Targeted Cerebral Vasospasm Protection Post-SAH
Nimotop (nimodipine) is a calcium channel blocker specifically formulated for the improvement of neurological outcomes by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage (SAH) from ruptured congenital intracranial aneurysms. Its cerebroselective mechanism targets cerebral arteries, offering a critical neuroprotective strategy during a vulnerable clinical period. Administered orally, it represents a cornerstone of post-SAH medical management, supported by extensive clinical evidence demonstrating its efficacy in preserving cognitive and motor function when initiated within 96 hours of the hemorrhage.
Actoplus Met: Dual-Action Control for Type 2 Diabetes
Actoplus Met combines two proven antihyperglycemic agents, pioglitazone and metformin, into a single tablet to provide comprehensive glycemic management for adults with type 2 diabetes mellitus. This fixed-dose combination therapy targets two key pathophysiological defects of the disease—insulin resistance and hepatic glucose overproduction—offering a synergistic approach to lower both fasting and postprandial blood glucose levels. By addressing multiple mechanisms simultaneously, it can simplify treatment regimens and improve adherence, which is critical for long-term metabolic control and reducing the risk of diabetes-related complications.
Actos: Advanced Type 2 Diabetes Management with Pioglitazone
Actos (pioglitazone hydrochloride) is a thiazolidinedione-class oral antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. By enhancing insulin sensitivity in peripheral tissues, it addresses core pathophysiological defects associated with the disease. This medication is designed for long-term management, helping to stabilize blood glucose levels and potentially reduce the risk of diabetic complications when used as part of a comprehensive treatment plan under medical supervision.
Amaryl: Advanced Glycemic Control for Type 2 Diabetes
Amaryl (glimepiride) is a second-generation sulfonylurea oral antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It functions primarily by stimulating insulin secretion from the pancreatic beta cells. This medication is recognized for its once-daily dosing convenience and its role in comprehensive diabetes management strategies, often used both as monotherapy and in combination with other antihyperglycemic agents when needed.
Baclofen: Effective Muscle Spasticity Relief for Enhanced Mobility
Baclofen is a centrally-acting skeletal muscle relaxant primarily indicated for the management of muscle spasticity. It functions as a gamma-aminobutyric acid (GABA) derivative, specifically targeting GABA-B receptors within the spinal cord to inhibit monosynaptic and polysynaptic reflex transmission. This pharmacological action results in reduced muscle tone and frequency of spasms, offering significant symptomatic relief for patients with neurological conditions. Clinicians value baclofen for its targeted mechanism and well-established efficacy profile in both oral and intrathecal formulations.
Baclosign: Targeted Spasticity Relief with Precision Muscle Relaxation
Baclosign (baclofen) is a centrally acting skeletal muscle relaxant specifically formulated for the management of spasticity resulting from multiple sclerosis, spinal cord injuries, and other neurological diseases. It operates as a gamma-aminobutyric acid (GABA) agonist, primarily exerting its effect at the spinal cord level to inhibit monosynaptic and polysynaptic reflex transmission. This targeted mechanism reduces the frequency and amplitude of muscle spasms, alleviates associated pain, and improves range of motion, thereby facilitating daily activities and therapeutic regimens.
Colospa: Targeted Relief for Irritable Bowel Syndrome Discomfort
Colospa (mebeverine hydrochloride) is an antispasmodic agent specifically formulated for the symptomatic management of Irritable Bowel Syndrome (IBS). It functions as a direct smooth muscle relaxant, acting predominantly on the gastrointestinal tract to alleviate spasmodic pain and cramping without affecting normal gut motility. By targeting the underlying muscle hyperactivity responsible for discomfort, Colospa provides focused relief, helping to restore daily comfort and function for individuals affected by IBS. Its selective action minimizes systemic side effects, making it a well-tolerated option for long-term symptom control.
Dapasmart: Advanced Relief for Intestinal Spasms and Motility Disorders
Dapasmart represents a significant advancement in the management of functional gastrointestinal disorders characterized by spasms and dysmotility. As a prescription medication containing the active ingredient Dicyclomine Hydrochloride, it operates as an antispasmodic and anticholinergic agent, specifically targeting the smooth muscle of the gastrointestinal tract. Its formulation is designed to provide predictable and effective relief, making it a cornerstone in therapeutic regimens for conditions like Irritable Bowel Syndrome (IBS). This product card provides a comprehensive, evidence-based overview for healthcare professionals to ensure informed prescribing and optimal patient outcomes.
DDAVP Spray: Advanced Vasopressin Therapy for Central Diabetes Insipidus
DDAVP Spray (desmopressin acetate) is a high-purity synthetic analogue of vasopressin, engineered for precise nasal delivery in the management of central diabetes insipidus. It directly addresses the underlying pathophysiology of vasopressin deficiency, restoring the body’s natural water balance mechanism. This formulation offers predictable pharmacokinetics and a favorable safety profile, making it a cornerstone of long-term endocrine therapy. Its non-invasive administration and rapid onset provide both clinical efficacy and patient convenience.